- Home
- SXTP vs SONN Comparison
SXTP vs SONN Comparison
Compare SXTP & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- SONN
- Stock Information
- Founded
- SXTP 2010
- SONN N/A
- Country
- SXTP United States
- SONN United States
- Employees
- SXTP N/A
- SONN N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- SONN Health Care
- Exchange
- SXTP Nasdaq
- SONN Nasdaq
- Market Cap
- SXTP 2.4M
- SONN 2.5M
- IPO Year
- SXTP 2023
- SONN N/A
- Fundamental
- Price
- SXTP $0.45
- SONN $1.44
- Analyst Decision
- SXTP Hold
- SONN Strong Buy
- Analyst Count
- SXTP 1
- SONN 2
- Target Price
- SXTP N/A
- SONN $38.00
- AVG Volume (30 Days)
- SXTP 5.8M
- SONN 98.6K
- Earning Date
- SXTP 03-31-2025
- SONN 02-13-2025
- Dividend Yield
- SXTP N/A
- SONN N/A
- EPS Growth
- SXTP N/A
- SONN N/A
- EPS
- SXTP N/A
- SONN N/A
- Revenue
- SXTP $462,612.00
- SONN $1,000,000.00
- Revenue This Year
- SXTP $141.35
- SONN N/A
- Revenue Next Year
- SXTP $175.16
- SONN N/A
- P/E Ratio
- SXTP N/A
- SONN N/A
- Revenue Growth
- SXTP 128.99
- SONN 674.14
- 52 Week Low
- SXTP $0.41
- SONN $1.38
- 52 Week High
- SXTP $7.20
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- SXTP 33.01
- SONN 37.03
- Support Level
- SXTP $0.47
- SONN $1.38
- Resistance Level
- SXTP $0.67
- SONN $1.60
- Average True Range (ATR)
- SXTP 0.10
- SONN 0.09
- MACD
- SXTP 0.00
- SONN -0.01
- Stochastic Oscillator
- SXTP 12.96
- SONN 19.35
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.